Abstract
Overactive bladder (OAB) is defined as urgency, with or without urge incontinence, usually with frequency and nocturia.1 It is a common condition with a significant impact on the quality of life.2 There are two primary approaches to the treatment of OAB; behavioral interventions and pharmacologic therapies. Both have been shown to produce significant reduction of OAB symptoms in large numbers of patients.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Abrams P, Cardozo L, Fall M, et al. The standardisation of terminology of lower urinary tract function. Report from the standardisation subcommittee of the International Continence Society. Urology. 2003;61:37.
Stewart WF, Van Rooyen JB, Cundiff GW, et al. Prevalence and burden of overactive bladder in the United States. World J Urol. 2003;20:327
Frewen WK. Role of bladder training in the treatment of the unstable bladder in the female. Urol Clin North Am. 1979;6:273–277.
Jarvis GJ, Millar DR. Controlled trial of bladder drill for detrusor instability. Br Med J. 1980;281: 322–1323.
Pengelly AW, Booth CM. A prospective trial of bladder training as treatment for detrusor instability. Br J Urol. 1980;52:463–466.
Fantl JA, Wyman JF, McClish DK, et al. Efficacy of bladder training in older women with urinary incontinence. JAMA. 1991;265:609–613.
Burgio KL, Whitehead WE, Engel BT. Urinary incontinence in the elderly: bladder/sphincter biofeedback and toileting skills training. Ann Intern Med 1985;103:507–515.
Burgio KL, Goode PS, Locher JL, et al. Behavioral training with and without biofeedback in the treatment of urge incontinence in older women: a randomized, controlled trial. JAMA. 2002;288:2293–2299.
Burgio KL, Pearce KL, Lucco A. Staying dry: A practical guide to bladder control. Baltimore: The Johns Hopkins University Press; 1989.
Burton JR, Pearce KL, Burgio KL, et al. Behavioral training for urinary incontinence in elderly ambulatory patients. J Am Geriatr Soc. 1988;36:693–698.
Burgio KL, Locher JL. Goode PS, et al. Behavioral vs. drug treatment for urge urinary incontinence in older women: a randomized controlled trial. JAMA. 1998;280:1995–2000.
Johnson TM, Burgio KL, Goode PS, et al. Effects of behavioral and drug therapy on nocturia in older incontinent women. J Am Geriatr Soc. 2005;53:846–850.
Moore KH, Hay DM, Imrie AE, et al. Oxybutynin hydrochloride (3 mg) in the treatment of women with idiopathic detrusor instability. Br J Urol. 1990;66:479–485.
Tapp AJS, Cardozo LD, Versi E, et al. The treatment of detrusor instability in post menopausal women with oxybutynin chloride: a double blind placebo-controlled study. Br J Obstet Gynaecol. 1990;97:479–485.
Thuroff JW, Bunke B, Ebner A, et al. Randomized, double-blind, multicentre trial on treatment of frequency, urgency and incontinence related to detrusor hyperactivity: oxybutynin versus propantheline versus placebo. J Urol. 1991;145;813–817.
Madersbacher H, Halaska M, Voigt R, et al. A placebo-controlled, multicentre study comparing the tolerability and efficacy of propiverine and oxybutynin in patients with urgency and urge incontinence. BJU Int. 1999;84:646–651.
Anderson RU, Mobley D, Blank B, et al. Once daily controlled versus immediate release oxybutynin chloride for urge urinary incontinence. OROS Oxybutynin Study Group J Urol. 1999;161:809–1812.
Gleason DM, Susset J, White C, et al. Evaluation of a new once-daily formulation of oxybutynin for the treatment of urinary urge incontinence. Ditropan XL Study Group. Urology. 1999;54:420–423.
Dmochowski RR, Sand PK, Zinner NR, et al. Transdermal Oxybutynin Study Group. Comparative efficacy and safety of transdermal oxybutynin and oral tolterodine versus placebo in previously treated patients with urge and mixed urinary incontinence. Urology. 2003;62:237–242.
Stoher M, Madersbacher H, Richter R, et al. Efficacy and safety of propiverine in SCI-patients suffering from detrusor hyperreflexia: a double-blind, placebo-controlled clinical trial. Spinal Cord. 1999;37:196–200.
Millard R, Tuttle J, Moore K, et al. Clinical efficacy and safety of tolterodine compared to placebo in detrusor overactivity. J Urol. 1999;161:1551–1555.
Rentzhog L. Stanton SL, Cardozo LD, et al. Efficacy and safety of tolterodine in patients with detrusor instability: a dose ranging study. Br J Urol. 1998;81:42–48.
Abrams P, Freeman R, Anderstrom C, et al. Tolterodine, a new antimuscarinic agent: as effective but better tolerated than oxybutynin in patients with an overactive bladder. Br J Urol. 1998;81:801–810.
Van Kerrebroeck P, Kreder K, Jonas U, et al. Tolt-erodine Study Group. Tolterodine once-daily: superior efficacy and tolerability in the treatment of overactive bladder. Urology. 2001;57:414–421.
Diokno AC, Appell RA, Sand PK, et al. OPERA Study Group. Prospective, randomised, double blind study of the efficacy and tolerability of the extended-release formulations of oxybutynin and tolterodine for overactive bladder: results of the OPERA trial. Mayo Clin Proc. 2003;78:687–695.
Cardozo LD, Chapple CR, Toozs-Hobson P, et al. Efficacy of trospium chloride in patients with detrusor instability: a placebo-controlled, randomized, double-blind, multicentre clinical trial. BJU Int. 2000;85:659–664.
Madersbacher H, Stoher M, Richter R, et al. Trospium chloride versus oxybutynin: a randomized, double-blind, multicentre trial in the treatment of detrusor hyperreflexia. Br J Urol 1995;75:452–456.
Ikeda K, Kobayashi S. Effects of YM905, Oxybutynin and Darifenacin on carbachol induced intracellular calcium mobilization by dispersed longitudinal smooth muscle cells of guinea pig colon. Yamanouchi Pharmaceutical Co. (1998). Registration No. D199803320-02.00. International Study ID: 905-PH-006.
Ikeda K, Kobayashi S. Effects of YM905, tolterodine and Oxybutynin on M3 receptor mediated cytosolic free Ca2+mobilization in acutely dissociated cells of guinea pig urinary bladder smooth muscle and murine submandibular gland. Yamanouchi Pharmaceutical Co. (1998). Registration No. D199803217-02.000. International Study ID: 905-PH-005.
Chapple C, Martinez-Garcia R Selvaggi L, et al A comparison of the efficacy and tolerability of Solifenacin Succinate and extended release Tolterodine at treating overactive bladder syndrome: results of the S.T.A.R trial. Eur Urol. 2005;48:464–470.
Rosario DJ, Leaker BR, Smith DJ, et al. A pilot study of the effects of multiple doses of the M3 muscarinic receptor antagonist darifenacin on ambulatory parameters of detrusor activity in patients with detrusor instability. Neurourol Urodyn. 1995;14:464–465.
Castleden CM, Duffin HM, Gulati RS. Double-blind study of imipramine and placebo for incontinence due to bladder instability. Age Ageing. 1986;15:299–303.
Robinson D, Cardozo L, Akeson M, et al. Women take control; Desmopressin — A drug for daytime urinary incontinence. Neurourol Urodyn. 2002;21:385–386.
Mattiasson AJ, et al. Simplified bladder training augments the effectiveness of tolterodine in patients with an overactive bladder. BJU Int. 2003;91:54–60.
Burgio KL, Locher JL, Goode PS. Combined behavioral and drug therapy for urge incontinence in older women. J Am Geriatr Soc. 2000;48:370–374.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2008 Springer-Verlag London Limited
About this chapter
Cite this chapter
Burgio, K.L., Robinson, D., Cardozo, L. (2008). Overactive Bladder. In: Baessler, K., Burgio, K.L., Norton, P.A., Schüssler, B., Moore, K.H., Stanton, S.L. (eds) Pelvic Floor Re-education. Springer, London. https://doi.org/10.1007/978-1-84628-505-9_29
Download citation
DOI: https://doi.org/10.1007/978-1-84628-505-9_29
Publisher Name: Springer, London
Print ISBN: 978-1-85233-968-5
Online ISBN: 978-1-84628-505-9
eBook Packages: MedicineMedicine (R0)